This suggests that, as the infection progresses, ongoing treatment with the CXCR4 antagonist may help restore immune balance, facilitate inflammation resolution, support stem cell mobilization for lung repair, and reduce fibrosis (65–69), ultimately promoting tissue recovery and enhancing overall survival. This evidence concerns the gene CXCR4 and infection.